Literature DB >> 18779609

Progress in small-cell lung cancer: the lowest common denominator.

David R Gandara, Primo N Lara, Ronald Natale, Chandra Belani.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18779609     DOI： 10.1200/JCO.2008.17.2692

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  PACE Continuous Innovation Indicators-a novel tool to measure progress in cancer treatments.

Authors:  Silvia Paddock; Lauren Brum; Kathleen Sorrow; Samuel Thomas; Susan Spence; Catharina Maulbecker-Armstrong; Clifford Goodman; Michael Peake; Gordon McVie; Gary Geipel; Rose Li
Journal:  Ecancermedicalscience       Date:  2015-01-07

2.  Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.

Authors:  Primo N Lara; Kari Chansky; Taro Shibata; Haruhiko Fukuda; Tomohide Tamura; John Crowley; Mary W Redman; Ronald Natale; Nagahiro Saijo; David R Gandara
Journal:  Cancer       Date:  2010-08-24       Impact factor: 6.860

3.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors:  Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

4.  Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.

Authors:  Mary W Redman; Bryan H Goldman; Michael LeBlanc; Anne Schott; Laurence H Baker
Journal:  Clin Cancer Res       Date:  2013-05-15       Impact factor: 12.531
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.